TABLE 2

Course of SUV in Responders and Nonresponders to Infliximab Therapy

Response according to criteria of European League Against RheumatismSUV
t = 0 wkt = 2 wk
Good (n = 5)55.6 ± 3.945.5 ± 11.0
Moderate (n = 8)48.7 ± 15.939.5 ± 14.1
None (n = 3)18.3 ± 10.433.5 ± 9.0
  • Mean SUV, averaged over all patients, was 44 ± 17 at baseline and 39 ± 12 at 2 wk.